PT  - JOURNAL ARTICLE
AU  - Wartak, Siddharth A.
AU  - Bartholomew, John R.
TI  - Dabigatran: Will it change clinical practice?
AID  - 10.3949/ccjm.78a.11021
DP  - 2011 Oct 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 657--664
VI  - 78
IP  - 10
4099  - http://www.ccjm.org/content/78/10/657.short
4100  - http://www.ccjm.org/content/78/10/657.full
SO  - Cleve Clin J Med2011 Oct 01; 78
AB  - Dabigatran (Pradaxa) is a new oral anticoagulant approved in the United States for the primary prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation. It offers clinicians an alternative to warfarin (Coumadin), and it has received considerable interest because of its convenience of use, clinical efficacy, and safety profile. However, it is more expensive, and this may limit its widespread use.